Kalaris Therapeutics reported financial results for the quarter ended June 30, 2026. The company incurred a net loss of $11.5 million and spent $9.0 million on research and development, compared to an $8.4 million R&D expense in the prior year period. General and administrative expenses decreased to $3.4 million from $3.8 million. As of June 30, 2026, Kalaris held $93.5 million in cash, cash equivalents, and marketable securities, which management expects will fund operations through the fourth quarter of 2027. The company is currently dosing patients in its Phase 1b/2 study of TH103 for neovascular Age-related Macular Degeneration, with preliminary data anticipated in the first half of 2027. Kalaris Therapeutics operates as a clinical-stage biopharmaceutical company dedicated to developing treatments for prevalent retinal diseases.

Kalaris Therapeutics, Inc. announced the appointment of Liisa Bayko as Chief Financial Officer and Treasurer, effective July 20, 2026, with an annualized base salary of $475,000 and a 40.0% target annual incentive bonus. Additionally, Brett Hagen resigned as Chief Accounting Officer effective July 27, 2026, and Amy Vandekop was designated as interim principal accounting officer effective the same date. Kalaris Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions.

Kalaris Therapeutics, Inc. announced positive additional data from its Phase 1a single ascending dose clinical trial of TH103 in treatment-naïve patients with neovascular age-related macular degeneration. The expanded dataset includes 17 treatment-naïve patients and 3 treatment-experienced patients, showing a9.2-letter mean BCVA improvement at one month and a 118µm mean CST improvement. Pharmacokinetic findings suggest greater intraocular retention compared to leading anti-VEGF agents. The company is actively enrolling and dosing patients in its ongoing Phase 0.5 Phase 1b/2 study, with preliminary data expected in the1H 2027. Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on retinal disease treatments.

On July 3, 2026, Morana Jovan-Embiricos, Ph.D., resigned from the board of directors and the Audit Committee, stating the decision was unrelated to any disagreement with company operations. On the same day, the board elected Laurie Keating to serve as a Class I director and member of the Audit Committee, effective August 1, 2026. Ms. Keating will receive $40,000 in annual cash board compensation, $7,500 for Audit Committee service, and an option to purchase 18,000 shares of common stock vesting monthly over three years. Kalaris Therapeutics, Inc. is a biotechnology company that develops therapeutic treatments.